Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Fat Substitutes”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 55 records · Page 3Linked to original sources
PubMed2005

Lipase-catalyzed acidolysis of tripalmitin with hazelnut oil fatty acids and stearic acid to produce human milk fat substitutes.

Structured lipids (SLs) containing palmitic, oleic, stearic, and linoleic acids, resembling human milk fat (HMF), were synthesized by enzymatic acidolysis reactions between tripalmitin, hazelnut oil fatty acids, and stearic acid. Commercially immobilized sn-1,3-specific lipase, Lipozyme RM IM, obtained from Rhizomucor miehei was used as the biocatalyst for the enzymatic acidolysis reactions. The effects of substrate molar ratio, reaction temperature, and reaction time on the incorporation of stearic and oleic acids were investigated. The acidolysis reactions were performed by incubating 1:1.5:0.5, 1:3:0.75, 1:6:1, 1:9:1.25, and 1:12:1.5 substrate molar ratios of tripalmitin/hazelnut oil fatty acids/stearic acid in 3 mL of n-hexane at 55, 60, and 65 degrees C using 10% (total weight of substrates) of Lipozyme RM IM for 3, 6, 12, and 24 h. The fatty acid composition of reaction products was analyzed by gas-liquid chromatography (GLC). The fatty acids at the sn-2 position were identified after pancreatic lipase hydrolysis and GLC analysis. The results showed that the highest C18:1 incorporation (47.1%) and highest C18:1/C16:0 ratio were obtained at 65 degrees C and 24 h of incubation with the highest substrate molar ratio of 1:12:1.5. The highest incorporation of stearic acid was achieved at a 1:3:0.75 substrate molar ratio at 60 degrees C and 24 h. For both oleic and stearic acids, the incorporation level increased with reaction time. The SLs produced in this study have potential use in infant formulas.

Corylus↗
PubMed1995

Nutrition evaluation of dietary fat substitutes.

In response to US dietary guidelines and health goals, the food industry has introduced a variety of innovative food products designed to help the American public lower its fat intake. The physical characteristics and safety considerations of these products are reviewed, as well as their association with chronic disease prevention.

Chronic Disease↗
PubMed1998

Overview of olestra: a new fat substitute.

Olestra is a mixture of hexa-, hepta- and octa-esters formed from the reaction of sucrase and long chain fatty acids isolated from edible oils. Olestra has properties similar to those of traditional triglycerides but is not hydrolyzed by pancreatic lipases and, therefore, serves as a noncaloric replacement for fats in the diet. The safety of olestra has been established in over 100 studies in seven different species of animals, with confirmatory safety data coming from approximately 75 human studies; consumption of olestra at levels typical for savoury snacks does not result in reports of gastrointestinal problems in humans. This is consistent with the results of studies of the physiological and morphological effects of olestra in animals and in humans. It is anticipated that olestra will be available in Canada in the near future. Patients will soon be asking their physicians about its use. This article provides an overview of olestra.

Canada↗
PubMed1999

A non-absorbable dietary fat substitute enhances elimination of persistent lipophilic contaminants in humans.

For individuals contaminated with persistent lipophilic pollutants, there is an urgent need for a therapy to enhance contaminant elimination from the body and hence reduce long term exposure. This study investigated the possibility of enhancing the excretion of native chemical via the faeces by augmenting the lipophilic properties of the faeces with the non-absorbable lipid substitute olestra. The faecal excretion of polychlorinated dibenzo-p-dioxins and dibenzofurans (PCDD/Fs), polychlorinated biphenyls (PCBs), and hexachlorobenzene (HCB) was measured in 3 volunteers. The excretion while eating an olestra-free diet was compared with the excretion while eating a diet supplemented wit 25 g/d of olestra. The excretion while on the olestra diet was higher by a factor of 1.5-11, depending on the compound. This resulted from higher concentrations of the contaminants in the faeces and higher excretion of faeces dry mass due to the food additive. Using 2,3,7,8-Cl4DD as an example, it was estimated that ingestion of 25 g/d of olestra would more than double the overall rate of elimination of this compound from the body. It is concluded that regular consumption of olestra may provide a therapeutic approach for reducing the body burden of persistent lipophilic contaminants.

Adipose Tissue↗